The pressure is on for biotech company Invex Therapeutics (ASX: IXC), which is not only struggling to recruit patients but is also dealing with underwhelming results for its flagship drug Presendin, tackling idiopathic intracranial hypertension (IIH). The Company has initiated a comprehensive assessment of its Phase IIH EVOLVE program, which explores the potential of Presendin
Read More
Imagine a headache so intense that the literal ear-throbbing pain results in blindness or other vision impairments. Even though sometimes it may not be so extreme, Idiopathic Intracranial Hypertension (IIH) can take such a form, making it integral to develop a cure for the same. Invex (ASX: IXC) believes that it has got one with
Read More